450 results on '"Pidala, J."'
Search Results
2. Directionality of non-permissive HLA-DPB1 T-cell epitope group mismatches does not improve clinical risk stratification in 8/8 matched unrelated donor hematopoietic cell transplantation
3. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention
4. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes
5. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation
6. Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors
7. 135 Association of patient-reported outcome measures with mortality in chronic skin GVHD
8. New sources for argument: do HLA-C and HLA disparity in adult double umbilical cord blood transplants predict outcomes?
9. P1318: THE IMPACT OF MELPHALAN DOSING IN COMBINATION WITH FLUDARABINE IN CLINICAL OUTCOMES OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES RECEIVING ALLO-HCT
10. Investigator feedback about the 2005 NIH diagnostic and scoring criteria for chronic GVHD
11. Clinical guide to fertility preservation in hematopoietic cell transplant recipients
12. Oral chronic GVHD outcomes and resource utilization: a subanalysis from the chronic GVHD consortium
13. Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation: a single institution experience
14. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease
15. Biologic markers of chronic GVHD
16. Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life
17. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission
18. Comorbidity burden in patients with chronic GVHD
19. A systematic review and meta-analysis of changes in cognitive functioning in adults undergoing hematopoietic cell transplantation
20. Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma
21. Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium
22. Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients
23. Impact of prior acute GVHD on chronic GVHD outcomes: a chronic graft versus host disease consortium study
24. Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization
25. Practice variation in physician referral for allogeneic hematopoietic cell transplantation
26. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis
27. Caregivers’ quality of life after blood and marrow transplantation: a qualitative study
28. Pulmonary alveolar proteinosis following allogeneic hematopoietic cell transplantation
29. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity
30. Sirolimus for treatment of steroid-refractory acute graft-versus-host disease
31. Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease
32. EARLY OCCURRENCE OF SEVERE HYPOALBUMINEMIA IS ASSOCIATED WITH ACUTE GVHD ONSET AND GRADING AFTER ALLOGENEIC HCT: PH-P410
33. Ustekinumab demonstrates activity in glucocorticoid-refractory acute GVHD
34. Reduced toxicity allogeneic HCT versus conventional chemo (-immunotherapy) in patients with relapsed or refractory CLL. Preliminary findings of a Markov decision analysis: O410
35. PS1549 SELF‐REPORTED PHYSICAL ACTIVITY IS PREDICTIVE OF SURVIVAL IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HCT)
36. Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia
37. Acceptability and Feasibility of a Mindfulness-Based Intervention Program for HCT Cancer Caregivers
38. Prospective assignment of HLA-DPB1 T cell epitope group mismatches by functional distance scores is significantly associated with outcome of 8/8 matched unrelated donor HCT
39. Uni-directional and bi-directional non-permissive HLA-DPB1 T cell epitope group mismatches have similar risk associations in 10/10 matched unrelated donor HCT
40. Visilizumab with tacrolimus and methotrexate for GvHD prevention after allogeneic hematopoietic cell transplantation from mismatched unrelated donors
41. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes
42. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation
43. Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research
44. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease
45. Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease
46. Quality of life associated with sirolimus for prevention of graft-versus-host disease: results from a randomized trial
47. Patient education in allogeneic hematopoietic cell transplant: what patients wish they had known about quality of life
48. Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors
49. Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission
50. Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.